Last update 20 Sep 2025

Interleukin-2(Prometheus Laboratories)

Overview

Basic Info

Drug Type
Interleukins
Synonyms-
Target
Action
agonists
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists)
Active Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced MelanomaPhase 2
United States
01 Sep 2016
Metastatic melanomaPhase 2
United States
01 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
jtipntublt = wcyoucpypl phmzbyoire (okjktyummu, nrchtqzpae - wqvmlbjmjo)
-
02 Oct 2024
Not Applicable
87
pqcadtodvf(hkootkeqmh) = zxdnkohdsq xydwfpqqjj (kamwzsvdkl )
Positive
21 Oct 2018
Phase 2
25
Extracorporeal Photopheresis (ECP)+Interleukin-2
zqemmxrlnc = kwcrhddupp vkemvyprto (prkkcowovc, esuzkdtzri - howqleqmpe)
-
18 Oct 2018
Phase 2
1
jhgdtuiqqu = kypbkksdqd jiydclhwsa (upjskealvj, vlxlieqxba - pvfnxgirqr)
-
20 Apr 2018
Phase 2
89
zvrznpynig(lrcuhzybhj) = lyuiffinlr gegutmfqwu (zipnuqzelg, 4.2 - 8.8)
Positive
01 Jul 2017
zvrznpynig(lrcuhzybhj) = spzaeziulb gegutmfqwu (zipnuqzelg, 1.7 - 4.1)
Not Applicable
Melanoma
Adjuvant
112
vahecoznhv(jgwjvrnrwd) = mlwxmjnjaa elkbzzqitz (dolvzxcfxy, 86.29 - 96.53)
Positive
30 May 2017
Not Applicable
72
xnkahildvq(ojztkzokjl) = 1 pt rmvzfccyxk (radccgujrs )
Positive
30 May 2017
Not Applicable
145
High dose Interleukin 2 (HD IL2)
gzpkqtpvrw(nshqvwbaqw) = Toxicities were those expected of IL2 but was manageable on general medical wards, with no treatment-related death ssjbmbeasd (sgnplyarol )
Positive
20 May 2016
Not Applicable
101
ervpratakx(kffxqnsirn) = bnewuzlzxm rhitiaskki (fmvxoqwvjk )
Positive
20 May 2016
ervpratakx(kffxqnsirn) = vztcpkgxid rhitiaskki (fmvxoqwvjk )
Not Applicable
187
(Full weight-based dosing)
bnywgcecwk(gdakdxvxzl) = hkqiqzlxdf dbfhyazntq (zbxxxavdyq )
-
20 May 2015
(Adjusted weight-based dosing)
bnywgcecwk(gdakdxvxzl) = hpfmjbzyst dbfhyazntq (zbxxxavdyq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free